Cambridge, UK – 10 June 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect. Dr Tansley steps into the role at a key development stage for Microbiotica with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis) with data read-outs anticipated this year. Dr Robert Tansley…

Life Science Agency CLOK are proud to announce the opening of new high-tech offices situated between Sherwood Pines and Center Parcs. Designed to support innovation and collaboration, the state-of-the-art space offers ultra-fast connectivity and top-tier facilities. A premium working environment reflects the organisations commitment to excellence, providing a clean air, friendly environment that is surrounded by acres of greenspace. The new office is located with excellent transport links for both clients and team members, with free on-site parking and great local amenities, including…

London, June 5th 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Melt&Marble and is pleased to announce the placement of Tue Hodal as its first Chief Technology Officer (CTO).Melt&Marble is a manufacturer of precision-fermented fats; the company has developed a proprietary technology designed to engineer yeast metabolism to produce tailored fats that meet specific functional and compositional requirements across various applications, including…

Read June eNews here  Featuring: Back in Boston, But It’s No Tea Party For All At The Moment, by Tony Jones, CEO, One Nucleus Key Reflections of the Boston Bootcamp 2025 by Alicia Gailliez, Business Development Manager, One Nucleus Is There An App For That? by Tony Jones, CEO, One Nucleus Connect with One Nucleus ar BIO and RESI Boston this June   Purchasing Scheme Update from Richard Dickinson, Chief Technical Specialist, One Nucleus Is 2025 the Year the Cambridge-to-Cambridge Bridge Really Flourishes? Tony's Jones' article in the Business Weekly newspaper #ONHelix25 Conference…

The May edition of our People Pathways newsletter is available to read here! Featuring: ✅ One Nucleus upcoming courses ✅ Training Highlights ✅ Top 3 reasons why you should attend our upcoming Introduction to Managing Life Science Projects - a short and fun video by our trainer John Faulkes...

Earlier this month, the House of Lords passed the Precision Breeding Act which has opened up a new world of opportunity for researchers and food biotech companies at Norwich Research Park. The Act allows for the gene editing of plants and crops in England, something Tropic, a food biotech company that has been based at Norwich Research Park for several years, is pioneering with crops grown in tropical regions of the world such as bananas and rice as well as closer to home with sugar beet. Gene editing enables precise, targeted changes to plant DNA to make improved varieties that are resistant…

Grant from the Gates Foundation to investigate efficient targeted DNA insertion Advance use of proprietary platform for next generation gene therapy applications CAMBRIDGE, UK, May 28, 2025 / Biotech Newswire / -- Gene Weaver Ltd (Gene Weaver), a biology technology innovator, has received $515,214 from the Gates Foundation to support the development of a next generation gene insertion tool. The grant will support work on Gene Weaver’s gene editing platform, and its potential to enable a low-cost option for protein therapeutics in low- and middle-income countries (LMIC). Cambridge-based Gene…

Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies Cambridge, UK and Marlborough, MA, 28 May 2025…

Amsbio has expanded its range of high-quality antibodies supporting standardization and Quality Assurance in the fast-growing stem cell research and therapeutic field. These optimized antibodies ensure reliable, accurate results in applications including flow cytometry, immunocytochemistry, Western blot, and ELISA. New additions to the range include monoclonal antibodies against key pluripotent stem cell markers: SSEA-3 (Gb5), SSEA-4 (SialylGb5), and Lewis X (SSEA-1). Stage-Specific Embryonic Antigens (SSEA) are glycan antigens known to vary in their…

Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision Norwich, UK, May 28 2025 – Ikarovec, a leader in ophthalmology innovation with a sophisticated field-…